Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
40 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.
Canaccord Genuity Maintains Buy on Homology Medicines, Lowers Price Target to $7
Canaccord Genuity analyst Michelle Gilson maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $19 to $7.
Homology Medicines’s Return On Capital Employed Overview
Benzinga Pro data, Homology Medicines (NASDAQ:FIXX) reported Q4 sales of $802.00 thousand. Earnings fell to a loss of $33.58 million, resulting in a 9.72% decrease from last quarter.
Homology Medicines Q4 EPS $(0.59) Up From $(0.62) YoY, Sales $800.00K Down From $980.00K YoY
Homology Medicines (NASDAQ:FIXX) reported quarterly losses of $(0.59) per share. This is a 4.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported $800.00 thousand in
Analyst Ratings For Homology Medicines
Analysts have provided the following ratings for Homology Medicines (NASDAQ:FIXX) within the last quarter:
42 Stocks Moving In Monday’s Mid-Day Session
Gainers
Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development.
Mid-Afternoon Market Update: US Stocks Pare Losses; Meritor Shares Spike Higher
U.S. stocks pared back some losses toward the end of trading on Tuesday. Russian President Vladimir Putin said he would recognize the independence of two Russian-led breakaway regions of Ukraine and ordered Russian troops to go into eastern Ukraine.
Analyst Ratings For Homology Medicines
Over the past 3 months, 4 analysts have published their opinion on Homology Medicines (NASDAQ:FIXX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.